Portal de investigación
Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Garcia-Alfonso, P.
- Saiz-Rodriguez, M.
- Mondejar, R.
- Salazar, J.
- Paez, D.
- Borobia, A. M.
- Safont, M. J.
- Garcia-Garcia, I
- Colomer, R.
- Garcia-Gonzalez, X.
- Lopez-Fernandez, L. A.
- Abad-Santos, F.
Grupos
Abstract
5-Fluorouracil (5-FU) and oral fluoropyrimidines, such as capecitabine, are widely used in the treatment of cancer, especially gastrointestinal tumors and breast cancer, but their administration can produce serious and even lethal toxicity. This toxicity is often related to the partial or complete deficiency of the dihydropyrimidine dehydrogenase (DPD) enzyme, which causes a reduction in clearance and a longer half-life of 5-FU. It is advisable to determine if a DPD deficiency exists before administering these drugs by genotyping DPYD gene polymorphisms. The objective of this consensus of experts, in which representatives from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology participated, is to establish clear recommendations for the implementation of genotype and/or phenotype testing for DPD deficiency in patients who are candidates to receive fluoropyrimidines. The genotyping of DPYD previous to treatment classifies individuals as normal, intermediate, or poor metabolizers. Normal metabolizers do not require changes in the initial dose, intermediate metabolizers should start treatment with fluoropyrimidines at doses reduced to 50%, and poor metabolizers are contraindicated for fluoropyrimidines.
© 2021. The Author(s).
Datos de la publicación
- ISSN/ISSNe:
- 1699-048X, 1699-3055
- Tipo:
- Article
- Páginas:
- 483-494
- Factor de Impacto:
- 0,764 SCImago ℠
- Cuartil:
- Q2 SCImago ℠
Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico SPRINGER-VERLAG ITALIA SRL
Citas Recibidas en Web of Science: 20
Documentos
- No hay documentos
Filiaciones
Keywords
- 5-fluorouracil, Capecitabine, Dihydropyrimidine dehydrogenase, Genotypes, Pharmacogenetics, Toxicity
Proyectos asociados
PLATAFORMA DE UNIDADES DE INVESTIGACION CLINICA Y ENSAYOS CLINICOS
Investigador Principal: JOSÉ VICENTE CASTELL RIPOLL
PT13/0002/0032 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
COMPREHENSIVE, INTEGRATIVE AND GENOMIC APPROACH TO THE UNDERSTANDING AND TREATMENT OF CANCER AND LEUKEMIA.
Investigador Principal: MIGUEL ÁNGEL SANZ ALONSO
PIE13/00046 . INSTITUTO DE SALUD CARLOS III; FUNDACIÓN PARA LA INVESTIGACIÓN DEL HOSPITAL UNIVERSITARIO LA FE DE LA COMUNIDAD VALENCIANA . 2014
IMPLANTACIÓN DE LA MEDICINA PERSONALIZADA EN ONCOLOGÍA PEDIÁTRICA: FARMACOGENÉTICA, EPIGENÉTICA, METABOLÓMICA Y LOS SISTEMAS DE INFORMACIÓN.
Investigador Principal: MARÍA JOSÉ HERRERO CERVERA
MJH-CIS-2016-01 . FUNDACION MUTUA MADRILEÑA . 2016
MODELOS DE HÍGADO AISLADO PERFUNDIDO PARA EL RESCATE DE ÓRGANOS Y TRASLACIÓN DE LA TERAPIA GÉNICA EN EL TRASPLANTE: ESCENARIOS HUMANO "EX VIVO" Y PORCINO "IN VIVO"
Investigador Principal: RAFAEL LÓPEZ ANDÚJAR
2017_0270_CRC_LOPEZ . FUNDACION MUTUA MADRILEÑA . 2017
Randomized, double-blind, placebo-controlled study to evaluate the effect of metformin, an activator of AMPK, on cognitive decline in patients with Huntington's disease. TEMET-HD
Investigador Principal: RAFAEL VÁZQUEZ MANRIQUE
ICI19/00014 . INSTITUTO DE SALUD CARLOS III . 2020
ESTUDIO FARMACOGENÉTICO DEL TRATAMIENTO EN LA INSUFICIENCIA CARDIACA TERMINAL: INHIBIDORES DE LA ECA, B-BLOQUEANTES Y ANTIALDOSTERÓNICOS.
Investigador Principal: MARÍA JOSÉ HERRERO CERVERA
HLF-ECA-2015-01
Cita
Garcia P,Saiz M,Mondejar R,Salazar J,Paez D,Borobia AM,Safont MJ,Garcia I,Colomer R,Garcia X,Herrero MJ,Lopez LA,Abad F. Consensus of experts from the Spanish Pharmacogenetics and Pharmacogenomics Society and the Spanish Society of Medical Oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clin Transl Oncol. 2022. 24. (3):p. 483-494. IF:3,400. (3).